OKYO Pharma Ltd. Form 6-K Summary
Reporting date: March 16, 2023. The filing reports an announcement by OKYO Pharma Ltd., a foreign private issuer that files annual reports on Form 20-F.
Business Context
The Company announced that its Phase 2 trial of OK-101 for the treatment of dry eye disease was listed on the ClinicalTrials.gov public website. The related news announcement was furnished as Exhibit 99.1.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
Material Changes
No financial or operational comparison with a prior period is provided. The principal reported development is the public listing of the OK-101 Phase 2 dry eye disease trial.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide financial guidance, trial timelines, enrollment details, clinical results, management outlook, risk updates, or contingency information. The filing states that the attached Exhibit 99.1 is furnished, not filed, and is generally not subject to Section 18 liability or incorporated by reference into other filings unless specifically stated.
Key Facts to Verify
- Review Exhibit 99.1 for the ClinicalTrials.gov identifier, trial design, endpoints, enrollment target, and expected timing.
- Verify the current status of the OK-101 Phase 2 trial directly on ClinicalTrials.gov.
- Consult the Company’s latest Form 20-F or subsequent filings for financial condition, liquidity, funding requirements, and material risks.